Everyone wants to know when we will be sure to COVID-19 The answer is, we’re probably in a long struggle. We are facing a persistent risk, maybe you get a vaccine until, or even after. But the risk can be managed and reduced, if we focus on assisting those with the greatest risk of contracting the disease. reliable test for the presence of antibodies (which say that he had the disease) will be very important. But we also need to show evidence that the virus carrying the disease in our society to find and people get access to treatment of individual cases before they turn into outbreaks and epidemics in a new epidemic. We have the technology and public health tools to achieve these goals, and new skills will be tested to climb rapidly develop faster. A crucial element for the future is the ability to access, reliable and affordable tests to bring people who have symptoms or are at risk, customers have the disease. This is not to say that we all need all the time on the screen. But for those who are symptomatic or have been exposed to the disease or for those who work in professions or live in communities where it is to ensure a greater probability of diffusion that we have the test. We largely rely on a reaction technology called polymerase chain reaction (PCR) in which buffers are used to collect samples, which are then boiled to the genetic material of the virus. This RNA is then amplified and analyzed to reveal the presence of active virus. But the process takes time, and the results may not be available for at least one day. to support the supply chain of these platforms PCR is also curious, and our network of laboratories is close to its limit. We carry out about 300,000 tests a day. Given constraints on logistics and supply chain, the upper limit is probably 500,000. New technologies are becoming available, the test is extended so that it is accessible, if you’re a large employer with a patient in a community setting or a college student returning to campus. The key will be equivalent to the own test solution on the right side of unmet medical need. The first test layer is advanced solutions for routine screening directly in a medical office. These include cars like the Abbott ID NOW test, which the White House is currently used and can give a result in five to 13 minutes. Cepheid GeneXpert produced a very accurate test system, the results to the treatment site in 30 to 45 minutes. approved this month, a quick test Quidel in the use of emergency authorization from the FDA. It protects for antigens that transmits the virus and gives a result within minutes. These tests are relatively inexpensive, easy and quick. Their limitation is that they are very specific, but (with the exception of GeneXpert), they are not equally sensitive. That is, if you say you have COVID-19, you can do almost surely. But sometimes it will say that you are not infected when you really are. In the hands of a health care professional, this test point-of-care testing can quickly help the majority of patients for diagnosis. For those, but got a negative test of suggestive symptoms, your doctor may send a PCR-based test to confirm and wait for the result. The next layer of the test is PCR machines more reliable results, but has everything to run to time. They will continue to play an important role when accuracy counts. But the widespread screening of the most common (think of a job that will on a regular basis all his staff screen), we need a third layer of tools that enable the rapid and accurate screening of large populations. For these operations, we should screen the many people with a high degree of precision machines, even if they have no symptoms. Consider a model in which the employees would spit in tubes and then the samples would be pooled in groups of 50 or even 100 and tested during the night to see if anyone has crown. If a sample pool is a success, the worker could be screened individually by PCR. I work with technologies and services that can be used for this type of screening in the workplace. These types of platforms are available now, and will be some large employers with their extensive screening to implement their workforce. to keep people safe requires tests that are simple, affordable and available. We must ensure that people who work or live in places that have a higher risk of these sets of access opportunities. Picture copyright by Caroline Brehman-CQ-Roll Call / Getty Images
Former FDA Commissioner: Here is the test strategy must certainly reopen America
